DK2125810T3 - Mapk/erk-kinaseinhibitorer - Google Patents

Mapk/erk-kinaseinhibitorer

Info

Publication number: DK2125810T3
Authority: DK; Denmark
Prior art keywords: mapk; kinase inhibitors; erk kinase; erk; inhibitors
Prior art date: 2006-12-20

Application number

DK07869422.1T

Other languages

English (en)

Inventor

Qing Dong

Xianchang Gong

Stephen W Kaldor

Nicholas Scorah

Michael B Wallace

Feng Zhou

Toufike Kanouni

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-20

Filing date

2007-12-18

Publication date

2013-07-29

2007-12-18 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2013-07-29 Application granted granted Critical

2013-07-29 Publication of DK2125810T3 publication Critical patent/DK2125810T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DK07869422.1T 2006-12-20 2007-12-18 Mapk/erk-kinaseinhibitorer DK2125810T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87091306P	2006-12-20	2006-12-20
PCT/US2007/087913 WO2008079814A2 (en)	2006-12-20	2007-12-18	Mapk/erk kinase inhibitors

Publications (1)

Publication Number	Publication Date
DK2125810T3 true DK2125810T3 (da)	2013-07-29

Family

ID=39462025

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK07869422.1T DK2125810T3 (da)	2006-12-20	2007-12-18	Mapk/erk-kinaseinhibitorer

Country Status (35)

Country	Link
US (4)	US8293901B2 (da)
EP (1)	EP2125810B1 (da)
JP (1)	JP5513127B2 (da)
KR (1)	KR101488467B1 (da)
CN (1)	CN101679411B (da)
AR (1)	AR064640A1 (da)
AU (1)	AU2007337003B2 (da)
BR (1)	BRPI0720525B8 (da)
CA (1)	CA2673647C (da)
CL (1)	CL2007003742A1 (da)
CO (1)	CO6230984A2 (da)
CR (1)	CR10937A (da)
DK (1)	DK2125810T3 (da)
EA (1)	EA016312B1 (da)
EC (1)	ECSP099529A (da)
ES (1)	ES2430966T3 (da)
GE (1)	GEP20125511B (da)
HR (1)	HRP20130684T1 (da)
IL (1)	IL199362A (da)
JO (1)	JO2985B1 (da)
MA (1)	MA31151B1 (da)
MX (1)	MX2009006675A (da)
MY (1)	MY157871A (da)
NO (1)	NO342270B1 (da)
NZ (1)	NZ578310A (da)
PE (1)	PE20090071A1 (da)
PL (1)	PL2125810T3 (da)
PT (1)	PT2125810E (da)
RS (1)	RS52887B (da)
SI (1)	SI2125810T1 (da)
TN (1)	TN2009000249A1 (da)
TW (1)	TWI396538B (da)
UA (1)	UA98479C2 (da)
WO (1)	WO2008079814A2 (da)
ZA (1)	ZA200904682B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1790649A1 (en) *	2005-11-21	2007-05-30	Sanofi-Aventis	Substituted bicyclic pyrimidone derivatives
TW200800997A (en) *	2006-03-22	2008-01-01	Astrazeneca Ab	Chemical compounds
EP2091941B1 (en) *	2006-10-23	2013-01-23	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors
JO2985B1 (ar) *	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
SA08280783B1 (ar) *	2007-01-11	2011-04-24	استرازينيكا ايه بي	مشتقات بيريدوبيريميدين كمثبطات pde4
JP5363350B2 (ja)	2007-03-19	2013-12-11	武田薬品工業株式会社	Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
CA2705452C (en) *	2007-11-12	2016-05-31	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors
US20090246198A1 (en) *	2008-03-31	2009-10-01	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors and methods of use thereof
JP2012509267A (ja)	2008-11-18	2012-04-19	武田薬品工業株式会社	（Ｒ）−３−（２，３−ジヒドロキシプロピル）−６−フルオロ−５−（２−フルオロ−４−ヨードフェニルアミノ）−８−メチルピリド［２，３−ｄ］ピリミジン−４，７（３Ｈ，８Ｈ）−ジオン及びその中間体を製造するためのプロセス
US20130315895A1 (en)	2010-07-01	2013-11-28	Takeda Pharmaceutical Company Limited	COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TWI505828B (zh) *	2010-12-20	2015-11-01	葛蘭素史克智慧財產（第二）有限公司	新穎醫藥組成物
TW201316991A (zh)	2011-06-03	2013-05-01	Millennium Pharm Inc	Ｍｅｋ抑制劑與奧諾拉（ａｕｒｏｒａ）ａ激酶選擇性抑制劑之組合
DK3321262T3 (da)	2012-03-01	2021-01-25	Array Biopharma Inc	Serin-/threoninkinasehæmmere
CA2868954A1 (en) *	2012-03-30	2013-10-03	Takeda Pharmaceutical Company Limited	Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma
CA2952992C (en) *	2014-06-17	2019-05-07	Cisen Pharmaceutical Co., Ltd.	Pyridino[1,2-a]pyrimidone analogue used as mtor/pi3k inhibitor
WO2016009306A1 (en) *	2014-07-15	2016-01-21	Lupin Limited	Heterocyclyl compounds as mek inhibitors
KR101671404B1 (ko) *	2014-09-02	2016-11-02	한국원자력의학원	항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
JP2016155776A (ja) *	2015-02-24	2016-09-01	学校法人兵庫医科大学	抗腫瘍効果増強剤および抗腫瘍剤
ES2876293T3 (es) *	2017-06-23	2021-11-12	Cstone Pharmaceuticals	Compuesto cíclico similar a la cumarina como inhibidor de MEK y uso del mismo
GB201713975D0 (en)	2017-08-31	2017-10-18	Macrophage Pharma Ltd	Medical use
US20220144819A1 (en) *	2018-11-20	2022-05-12	Nflection Therapeutics, Inc.	Naphthyridinone-aniline compounds for treatment of dermal disorders
TWI825637B (zh) *	2021-03-31	2023-12-11	美商輝瑞股份有限公司	啶－１，６（２ｈ，７ｈ）－二酮
CN117779203B (zh) *	2024-02-28	2024-05-31	西北工业大学	一种n-苄基-2-甲基-4-硝基苯胺单晶及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5430148A (en)	1992-03-31	1995-07-04	Agouron Pharmaceuticals, Inc.	Antiproliferative quinazolines
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
CA2355470C (en)	1999-01-13	2008-09-30	Warner-Lambert Company	Benzoheterocycles and their use as mek inhibitors
EA200200643A1 (ru)	2000-01-25	2002-12-26	Уорнер-Ламберт Компани	ПИРИДО[2,3-d]ПИРИМИДИН-2,7-ДИАМИНОВЫЕ ИНГИБИТОРЫ КИНАЗ
OA12333A (en)	2000-07-19	2004-04-06	Warner Lambert Co	Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids.
BR0114829A (pt)	2000-10-23	2003-09-23	Smithkline Beecham Corp	Novos compostos
US6825180B2 (en)	2001-05-18	2004-11-30	Cell Therapeutics, Inc.	Pyridopyrimidine compounds and their uses
HUE025767T2 (en)	2002-03-13	2016-05-30	Array Biopharma Inc	N3-alkylated benzimidazole derivatives as MEK inhibitors
UA76837C2 (uk)	2002-03-13	2006-09-15	Еррей Байофарма Інк.	N3 алкіловані похідні бензімідазолу як інгібітори мек
SI1636228T1 (sl)	2003-05-23	2009-04-30	Aeterna Zentaris Gmbh	Novi piridopirazini in uporaba le-teh kot modulatorjev kinaz
AU2003277715A1 (en)	2003-07-03	2005-01-21	Sunghag Koo	Ferment ginseng oil
WO2005009975A2 (en)	2003-07-24	2005-02-03	Warner-Lambert Company Llc	Benzimidazole derivatives as mek inhibitors
JP2007500725A (ja)	2003-07-29	2007-01-18	アイアールエム・リミテッド・ライアビリティ・カンパニー	プロテインキナーゼ阻害剤としての化合物および組成物
PT1689387E (pt)	2003-11-19	2011-09-28	Array Biopharma Inc	Inibidores bicíclicos de mek e seus métodos de síntese
KR100883289B1 (ko)	2004-06-11	2009-02-11	니뽄 다바코 산교 가부시키가이샤	암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
US7378423B2 (en)	2004-06-11	2008-05-27	Japan Tobacco Inc.	Pyrimidine compound and medical use thereof
DE102004054215A1 (de)	2004-11-10	2006-05-11	Merck Patent Gmbh	Pyridopyrimidinonderivate
ATE443063T1 (de)	2004-12-01	2009-10-15	Merck Serono Sa	Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
EP2044068A4 (en)	2006-07-17	2010-07-21	Merck Sharp & Dohme	1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS
EP2091941B1 (en) *	2006-10-23	2013-01-23	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors
WO2008055842A1 (en)	2006-11-09	2008-05-15	F. Hoffmann-La Roche Ag	Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
JO2985B1 (ar) *	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
CA2705452C (en)	2007-11-12	2016-05-31	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors
US20090246198A1 (en)	2008-03-31	2009-10-01	Takeda Pharmaceutical Company Limited	Mapk/erk kinase inhibitors and methods of use thereof
JP2012509267A (ja)	2008-11-18	2012-04-19	武田薬品工業株式会社	（Ｒ）−３−（２，３−ジヒドロキシプロピル）−６−フルオロ−５−（２−フルオロ−４−ヨードフェニルアミノ）−８−メチルピリド［２，３−ｄ］ピリミジン−４，７（３Ｈ，８Ｈ）−ジオン及びその中間体を製造するためのプロセス

2007
- 2007-12-17 JO JOP/2007/0555A patent/JO2985B1/ar active
- 2007-12-18 GE GEAP200711376A patent/GEP20125511B/en unknown
- 2007-12-18 US US12/520,247 patent/US8293901B2/en active Active
- 2007-12-18 ES ES07869422T patent/ES2430966T3/es active Active
- 2007-12-18 EP EP07869422.1A patent/EP2125810B1/en active Active
- 2007-12-18 RS RS20130315A patent/RS52887B/en unknown
- 2007-12-18 JP JP2009543137A patent/JP5513127B2/ja active Active
- 2007-12-18 US US11/958,999 patent/US8030317B2/en active Active
- 2007-12-18 BR BRPI0720525A patent/BRPI0720525B8/pt active IP Right Grant
- 2007-12-18 MX MX2009006675A patent/MX2009006675A/es active IP Right Grant
- 2007-12-18 AU AU2007337003A patent/AU2007337003B2/en active Active
- 2007-12-18 DK DK07869422.1T patent/DK2125810T3/da active
- 2007-12-18 MY MYPI20092545A patent/MY157871A/en unknown
- 2007-12-18 SI SI200731281T patent/SI2125810T1/sl unknown
- 2007-12-18 UA UAA200907471A patent/UA98479C2/ru unknown
- 2007-12-18 NZ NZ578310A patent/NZ578310A/en unknown
- 2007-12-18 EA EA200970605A patent/EA016312B1/ru unknown
- 2007-12-18 KR KR20097015218A patent/KR101488467B1/ko active IP Right Grant
- 2007-12-18 ZA ZA200904682A patent/ZA200904682B/xx unknown
- 2007-12-18 PL PL07869422T patent/PL2125810T3/pl unknown
- 2007-12-18 WO PCT/US2007/087913 patent/WO2008079814A2/en active Application Filing
- 2007-12-18 CA CA2673647A patent/CA2673647C/en active Active
- 2007-12-18 CN CN2007800503244A patent/CN101679411B/zh active Active
- 2007-12-18 PT PT78694221T patent/PT2125810E/pt unknown
- 2007-12-20 CL CL200703742A patent/CL2007003742A1/es unknown
- 2007-12-20 TW TW096149026A patent/TWI396538B/zh active
- 2007-12-20 AR ARP070105806A patent/AR064640A1/es active IP Right Grant
2008
- 2008-01-02 PE PE2008000065A patent/PE20090071A1/es active IP Right Grant
2009
- 2009-06-15 IL IL199362A patent/IL199362A/en active IP Right Grant
- 2009-06-17 TN TNP2009000249A patent/TN2009000249A1/fr unknown
- 2009-07-10 MA MA32088A patent/MA31151B1/fr unknown
- 2009-07-15 NO NO20092692A patent/NO342270B1/no unknown
- 2009-07-17 CO CO09074721A patent/CO6230984A2/es active IP Right Grant
- 2009-07-17 CR CR10937A patent/CR10937A/es unknown
- 2009-07-21 EC EC2009009529A patent/ECSP099529A/es unknown
2010
- 2010-10-07 US US12/900,350 patent/US20110065733A1/en not_active Abandoned
2012
- 2012-04-18 US US13/450,064 patent/US8470837B2/en active Active
2013
- 2013-07-22 HR HRP20130684TT patent/HRP20130684T1/hr unknown

Also Published As

Publication number	Publication date
TN2009000249A1 (en)	2010-10-18
US8293901B2 (en)	2012-10-23
ZA200904682B (en)	2010-09-29
US20110065733A1 (en)	2011-03-17
EP2125810B1 (en)	2013-04-24
US20080255160A1 (en)	2008-10-16
AR064640A1 (es)	2009-04-15
SI2125810T1 (sl)	2013-09-30
PL2125810T3 (pl)	2013-09-30
MY157871A (en)	2016-07-29
BRPI0720525A2 (pt)	2014-01-07
HRP20130684T1 (en)	2013-10-11
CR10937A (es)	2009-11-20
RS52887B (en)	2014-02-28
BRPI0720525B8 (pt)	2021-05-25
ECSP099529A (es)	2009-08-28
AU2007337003B2 (en)	2013-05-02
PE20090071A1 (es)	2009-04-04
BRPI0720525B1 (pt)	2020-03-03
EA016312B1 (ru)	2012-04-30
TW200835496A (en)	2008-09-01
CN101679411A (zh)	2010-03-24
IL199362A (en)	2013-07-31
US8470837B2 (en)	2013-06-25
US8030317B2 (en)	2011-10-04
NO342270B1 (no)	2018-04-30
JP5513127B2 (ja)	2014-06-04
WO2008079814A2 (en)	2008-07-03
MX2009006675A (es)	2009-08-12
ES2430966T3 (es)	2013-11-22
CA2673647C (en)	2016-02-09
WO2008079814A3 (en)	2008-09-04
NO20092692L (no)	2009-09-16
JO2985B1 (ar)	2016-09-05
CL2007003742A1 (es)	2008-06-13
NZ578310A (en)	2012-01-12
JP2010514680A (ja)	2010-05-06
EA200970605A1 (ru)	2009-12-30
AU2007337003A2 (en)	2009-07-30
US20100130518A1 (en)	2010-05-27
CN101679411B (zh)	2013-04-17
KR101488467B1 (ko)	2015-01-30
EP2125810A2 (en)	2009-12-02
GEP20125511B (en)	2012-05-10
CO6230984A2 (es)	2010-12-20
CA2673647A1 (en)	2008-07-03
MA31151B1 (fr)	2010-02-01
PT2125810E (pt)	2013-07-29
US20120202999A1 (en)	2012-08-09
TWI396538B (zh)	2013-05-21
AU2007337003A1 (en)	2008-07-03
UA98479C2 (en)	2012-05-25
KR20090091353A (ko)	2009-08-27

Publication	Publication Date	Title
DK2125810T3 (da)	2013-07-29	Mapk/erk-kinaseinhibitorer
CY2021013I2 (el)	2021-12-31	Δι-αρυλ μετα-πυριμιδινο αναστολεις κινασων
CY2019009I2 (el)	2019-11-27	Αναστολεις πρωτεϊνικων κινασων
CY2017012I1 (el)	2017-11-14	Αναστολεις κινασης τυροσινης bruton
CY2017016I2 (el)	2017-07-12	Αναστολεις πρωτεασωματος
BRPI0716781A2 (pt)	2014-11-18	Inibidores da quinase
DK2041138T3 (da)	2014-08-11	Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da)	2011-06-27	Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
BRPI0811212A2 (pt)	2014-10-29	Inibidores de p70 quinase
DK2099447T3 (da)	2013-02-18	Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
CR10831A (es)	2009-06-18	INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2086939T3 (da)	2010-10-11	Pyridiacarboxamid som II-beta-HSDI-inhibitorer
ATE488505T1 (de)	2010-12-15	Kinasehemmer auf hydantoinbasis
DK2125748T3 (da)	2011-08-01	Acylaminopyrazol som FGFR inhibitorer
DK1943243T3 (da)	2011-03-07	Kinase-inhibitorer
BRPI0810374A2 (pt)	2014-10-29	Inibidores específicos do pdgfrbeta
DK2013175T5 (da)	2020-12-21	p38 Map-kinase-inhibitorer
BRPI0814797A2 (pt)	2015-02-03	Inibidores dna-pk
DK2035385T3 (da)	2010-03-22	Inhibitorer af akt (proteinkinase B)
DK2358710T3 (da)	2012-09-03	AKT- og P70-S6-kinaseinhibitorer
DK2066662T3 (da)	2013-01-07	Serinhydrolaseinhibitorer
IL198254A0 (en)	2009-12-24	Mapk/erk kinase inhibitors
ATE433449T1 (de)	2009-06-15	Kinaseinhibitoren
DK2170891T3 (da)	2011-12-12	Pyrazolopyrimidinon-kinasehæmmere
BRPI0719883A2 (pt)	2015-05-05	Inibidores de quinase